Respiratory Oxygen Adherence Monitor for COPD Patients - PROJECT SUMMARY/ABSTRACT
Introduction: The Respiratory Oxygen Adherence Monitor (ROAM) system will provide an effective, practical,
and affordable method to reliably assess long term oxygen therapy (LTOT) adherence.
Problem to be Addressed: Chronic obstructive pulmonary disease (COPD) afflicts over 15 million people in the
United States a n d is responsible for over 500,000 hospitalizations and over 100,000 deaths annually. LTOT,
which is generally administered to patients via a nasal cannula attached to an oxygen source, is the only
treatment that has been shown to improve survival in severe hypoxemia due to cardiopulmonary disease. The
improvement in mortality is greatest when oxygen therapy is used at least 16 hours/day. LTOT is also associated
with significant reductions in hospitalizations and lengths of stay, and improved quality of life. Despite the
benefits of LTOT, adherence remains a challenge in the majority of patients. Furthermore, the ability to
accurately assess rates of patient LTOT adherence is limited by current measures, such as power‐on time of the
concentrator, which fail to discern whether the patient is actually wearing the nasal cannula and inhaling oxygen,
as opposed to merely having the oxygen source turned on. Present measures also fail to provide information
regarding the pattern of oxygen use within each 24‐hour interval. An objective and accurate method for
measuring patient adherence to LTOT is required to augment clinical effectiveness.
Research Hypotheses: The SBIR Phase I program will test the hypothesis that the ROAM system can accurately
track adherent and non‐adherent patients during laboratory validation studies.
Phase I Summary: In the proposed research effort, the team will develop a commercial‐ready ROAM system
using hardware components and the inclusion of a software interface that enables patients and authorized
healthcare providers to access to patients' adherence data, including pulse oximetry measures. The system will
provide patients with informational, attentional, and motivational feedback to encourage and improve
adherence. User‐design processes will be implemented for hardware and software development to ensure
usability and motivational relevance with the target patient population. The Phase II program will culminate in
an extensive field trial involving COPD patients to demonstrate system efficacy.
Public Health Impact: The ROAM system will increase LTOT adherence, lead to improved health outcomes
for patients with cardiopulmonary disease, and reduce the healthcare costs that are associated with expensive
and preventable hospitalizations due to non‐adherence.
